A Novel Glucagon Receptor Antagonist, NNC 25-0926, Blunts Hepatic Glucose Production in the Conscious Dog-Reference-Cited by-同舟云学术

A Novel Glucagon Receptor Antagonist, NNC 25-0926, Blunts Hepatic Glucose Production in the Conscious Dog

Published:2007-02-16 Issue:2 Volume:321 Page:743-752
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Rivera Noelia,Everett-Grueter Carrie A.,Edgerton Dale S.,Rodewald Tiffany,Neal Doss W.,Nishimura Erica,Larsen Marianne O.,Jacobsen Lene O.,Kristensen Kim,Brand Christian L.,Cherrington Alan D.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference40 articles.

1. Signals mediating cleavage of intercellular adhesion molecule-1

2. Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats

3. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo.

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The glucagon-receptor antagonist MK-3577 reduces glucagon-stimulated plasma glucose and insulin concentrations in metabolically healthy overweight cats;Domestic Animal Endocrinology;2024-10

2. Regulation of Hepatic Lipid and Glucose Metabolism by INSP3R1;Diabetes;2022-06-03

3. Optimization of Truncated Glucagon Peptides to Achieve Selective, High Potency, Full Antagonists;Journal of Medicinal Chemistry;2021-04-06

4. Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study;Diabetes Care;2019-11-06

5. Discovery of potent and orally bioavailable indazole-based glucagon receptor antagonists for the treatment of type 2 diabetes;Bioorganic & Medicinal Chemistry Letters;2019-10